Citigroup Issues Positive Forecast for Scholar Rock (NASDAQ:SRRK) Stock Price

Scholar Rock (NASDAQ:SRRK) had its price target raised by analysts at Citigroup from $55.00 to $58.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s target price indicates a potential upside of 26.69% from the company’s current price.

A number of other equities analysts have also recently commented on SRRK. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a report on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Scholar Rock in a research note on Tuesday. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Scholar Rock in a research report on Tuesday. Piper Sandler increased their target price on shares of Scholar Rock from $51.00 to $58.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Barclays lifted their price target on shares of Scholar Rock from $52.00 to $53.00 and gave the company an “overweight” rating in a report on Tuesday. Four research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $54.14.

Scholar Rock Stock Performance

Shares of NASDAQ:SRRK traded up $1.47 during trading on Wednesday, hitting $45.78. The company’s stock had a trading volume of 2,710,176 shares, compared to its average volume of 1,067,223. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.30 and a quick ratio of 6.30. The firm has a market cap of $4.67 billion, a price-to-earnings ratio of -14.53 and a beta of 0.70. The company has a 50-day moving average of $45.29 and a 200-day moving average of $39.08. Scholar Rock has a 12 month low of $22.71 and a 12 month high of $49.82.

Scholar Rock (NASDAQ:SRRK) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.10. During the same quarter in the previous year, the firm earned ($0.64) EPS. On average, sell-side analysts expect that Scholar Rock will post -2.42 earnings per share for the current year.

Insiders Place Their Bets

In other Scholar Rock news, insider Mo Qatanani sold 136,462 shares of Scholar Rock stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $45.21, for a total value of $6,169,447.02. Following the sale, the insider directly owned 108,964 shares in the company, valued at approximately $4,926,262.44. The trade was a 55.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Keith Woods sold 16,746 shares of the business’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total transaction of $715,054.20. Following the completion of the sale, the chief operating officer owned 583,254 shares in the company, valued at approximately $24,904,945.80. The trade was a 2.79% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 344,932 shares of company stock worth $15,371,225 over the last ninety days. 13.30% of the stock is owned by company insiders.

Institutional Trading of Scholar Rock

A number of large investors have recently made changes to their positions in the business. AQR Capital Management LLC raised its holdings in shares of Scholar Rock by 609.3% in the first quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock worth $1,842,000 after buying an additional 49,217 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Scholar Rock by 12.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock valued at $1,709,000 after acquiring an additional 5,831 shares during the last quarter. Millennium Management LLC increased its stake in Scholar Rock by 37.4% in the first quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock worth $6,438,000 after purchasing an additional 54,555 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Scholar Rock by 25.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock worth $5,460,000 after purchasing an additional 34,594 shares during the last quarter. Finally, Strs Ohio purchased a new stake in shares of Scholar Rock during the first quarter valued at $77,000. 91.08% of the stock is currently owned by institutional investors.

Trending Headlines about Scholar Rock

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: Piper Sandler raised its price target to $58 and initiated/maintained an “overweight” view, implying ~31.5% upside from recent levels — a clear catalyst for buying interest. We are incrementally positive on Scholar Rock (SRRK) Shares; PT Raised at Piper Sandler
• Positive Sentiment: HC Wainwright reaffirmed a “buy” and set a $58 price target, reinforcing analyst optimism and supporting momentum. HC Wainwright Reaffirms Buy; $58 PT
• Positive Sentiment: Q4 2025 results beat consensus — reported EPS/loss was better than expectations (company reported a smaller-than-expected loss), which traders interpret as operational progress ahead of key clinical milestones. Scholar Rock Q4 2025 Press Release / Financial Results
• Neutral Sentiment: Multiple transcripts and call coverage (Seeking Alpha, InsiderMonkey, Yahoo Finance) are available for the Q4 earnings call — useful for investors digging into management commentary on pipelines, cash runway and upcoming catalysts but not a direct immediate catalyst by itself. Q4 2025 Earnings Call Transcript (InsiderMonkey)
• Negative Sentiment: The company acknowledged a correcting press release: while the quarter beat estimates, net loss widened year‑over‑year (reported net loss per share larger than the year‑ago quarter), which could temper enthusiasm until clinical/financial trends become clearer. Correcting and Replacing: Q4 & Full Year 2025 Financial Results

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).